Exact Mass: 462.0917

Exact Mass Matches: 462.0917

Found 38 metabolites which its exact mass value is equals to given mass value 462.0917, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

farnesyl triphosphate

3,7,11-trimethyldodeca-2,6,10-trien-1-yl tetrahydrogen triphosphate

C15H29O10P3 (462.0974)


   

Oxazepam glucuronide

(2S,3S,4S,5R,6S)-6-[(7-chloro-2-hydroxy-5-phenyl-3H-1,4-benzodiazepin-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C21H19ClN2O8 (462.083)


Oxazepam glucuronide belongs to the family of Glucuronic Acid Derivatives. These are compounds containing a glucuronic acid moeity (or a derivative), which consists of a glucose moiety with the C6 carbon oxidized to a carboxylic acid.

   

2-Ethoxy-3-[4-[2-[4-(trifluoromethylsulfonyloxy)phenyl]ethoxy]phenyl]propanoic acid

2-Ethoxy-3-[4-[2-[4-(trifluoromethylsulphonyloxy)phenyl]ethoxy]phenyl]propanoic acid

C20H21F3O7S (462.096)


   

Antibiotic DC 116

Antibiotic DC 116

C25H18O9 (462.0951)


   

inoscavin A

inoscavin A

C25H18O9 (462.0951)


   
   

Oxazepam glucuronide

Oxazepam glucuronide

C21H19ClN2O8 (462.083)


   
   

Eletriptan HBr

Eletriptan hydrobromide

C22H27BrN2O2S (462.0977)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Eletriptan hydrobromide (Eletriptan HBr) is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively.

   

prohexadione-calcium

prohexadione-calcium

C20H22CaO10 (462.0839)


   

Dodecafluoroheptylpropyl methyl dimethoxysilane

Dodecafluoroheptylpropyl methyl dimethoxysilane

C13H18F12O2Si (462.0884)


   
   

Rintodestrant

Rintodestrant

C26H19FO5S (462.0937)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2116 - Selective Estrogen Receptor Down Regulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist

   

[4-[(Z)-[3-(2-aminoethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-2-methoxyphenyl] 2,5-dimethylbenzenesulfonate

[4-[(Z)-[3-(2-aminoethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-2-methoxyphenyl] 2,5-dimethylbenzenesulfonate

C21H22N2O6S2 (462.0919)


   

Aspartyl-adenosine-5-monophosphate

Aspartyl-adenosine-5-monophosphate

C14H19N6O10P (462.09)


   

7-(Methylthio)heptyl-glucosinolate

7-(Methylthio)heptyl-glucosinolate

C15H28NO9S3- (462.0926)


   

7-(3,4-Dihydroxyphenyl)-4-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one

7-(3,4-Dihydroxyphenyl)-4-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)-2,8-dioxatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),6,9-pentaen-11-one

C25H18O9 (462.0951)


   

3-L-aspartyl-AMP

3-L-aspartyl-AMP

C14H19N6O10P (462.09)


An L-aspartic acid derivative that is the ester obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the 3-hydroxy group of AMP.

   

4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide

4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide

C23H18N4O5S (462.0998)


   

6-[1-oxo-2-[[4-(phenylmethyl)-5-thiophen-2-yl-1,2,4-triazol-3-yl]thio]ethyl]-4H-1,4-benzoxazin-3-one

6-[1-oxo-2-[[4-(phenylmethyl)-5-thiophen-2-yl-1,2,4-triazol-3-yl]thio]ethyl]-4H-1,4-benzoxazin-3-one

C23H18N4O3S2 (462.082)


   

2-acetamido-2-deoxy-3-O-(6-O-sulfonato-beta-D-glucosyl)-beta-D-galactose

2-acetamido-2-deoxy-3-O-(6-O-sulfonato-beta-D-glucosyl)-beta-D-galactose

C14H24NO14S- (462.0917)


   

(2S,3S,4S,5R)-6-[(7-Chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

(2S,3S,4S,5R)-6-[(7-Chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C21H19ClN2O8 (462.083)


   

(2S)-2-[[2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid

(2S)-2-[[2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid

C14H19N6O10P (462.09)


   

N6-Succino-2-amino-2'-deoxyadenylate

N6-Succino-2-amino-2'-deoxyadenylate

C14H19N6O10P (462.09)


   

MDM2-IN-1

MDM2-IN-1

C23H21Cl2FN2O3 (462.0913)


MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration[1].

   

4,12-bis(but-2-en-2-yl)-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

4,12-bis(but-2-en-2-yl)-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

C24H24Cl2O5 (462.1001)


   

2'-(3,4-dihydroxyphenyl)-6'-[2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione

2'-(3,4-dihydroxyphenyl)-6'-[2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione

C25H18O9 (462.0951)


   

{8,11-dihydroxy-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid

{8,11-dihydroxy-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid

C25H18O9 (462.0951)


   

3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one

3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one

C25H18O9 (462.0951)


   

4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione

4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione

C24H24Cl2O5 (462.1001)


   

(2s,2's)-2'-(3,4-dihydroxyphenyl)-6'-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione

(2s,2's)-2'-(3,4-dihydroxyphenyl)-6'-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-5-methyl-2'h-spiro[furan-2,3'-furo[3,2-c]pyran]-3,4'-dione

C25H18O9 (462.0951)


   

4,12-bis[(2e)-but-2-en-2-yl]-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

4,12-bis[(2e)-but-2-en-2-yl]-5,13-dichloro-14-hydroxy-6-methoxy-7,15-dimethyl-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

C24H24Cl2O5 (462.1001)


   

{8,11-dihydroxy-2-[(2s,3s)-2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid

{8,11-dihydroxy-2-[(2s,3s)-2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl]-4,7,12-trioxo-1-oxatetraphen-5-yl}acetic acid

C25H18O9 (462.0951)


   

(2r,2'r,3s,3'r,3'ar)-3'-hydroxy-5'-methyl-3,3'a-bis(methylsulfanyl)-3h,3'h-dispiro[1-benzofuran-2,6'-[1,2]oxazolo[2,3-a]pyrazine-2',1''-cyclohexan]-3''-ene-2'',4',7'-trione

(2r,2'r,3s,3'r,3'ar)-3'-hydroxy-5'-methyl-3,3'a-bis(methylsulfanyl)-3h,3'h-dispiro[1-benzofuran-2,6'-[1,2]oxazolo[2,3-a]pyrazine-2',1''-cyclohexan]-3''-ene-2'',4',7'-trione

C21H22N2O6S2 (462.0919)


   

(1s,4r,6r,14e,17e)-4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione

(1s,4r,6r,14e,17e)-4,6-dichloro-9-hydroxy-3,3,17-trimethyl-2,12-dioxapentacyclo[9.8.3.1¹⁰,¹⁴.0¹,⁶.0⁸,²¹]tricosa-8(21),9,11(22),14,17-pentaene-7,20-dione

C24H24Cl2O5 (462.1001)


   

3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one

3-[4,5-dihydroxy-2-(6-methyl-4-oxopyran-2-yl)phenyl]-6-[2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxypyran-2-one

C25H18O9 (462.0951)